ALZPROTECT
- Biotech or pharma, therapeutic R&D
Alzprotect is developing Ezeprogind® (AZP2006), a first-in-class dual prosaposin (PSAP) and progranulin (PGRN) pharmaco-chaperone targeting lysosomal dysfunction—an essential and under-addressed mechanism in neurodegenerative diseases.
Ezeprogind® has blockbuster potential by addressing fundamental defects in the lysosomal pathway, a convergent node in the pathophysiology of several neurodegenerative disorders.
The program is advancing toward a pivotal Phase 2/3 clinical trial in progressive supranuclear palsy (PSP). Additionally, Ezeprogind® is Phase 2–ready for Alzheimer’s and Parkinson’s disease, broadening its potential as a platform therapy.
We are seeking strategic partnerships to accelerate development and maximize the impact of this transformative therapy.
We will be focusing on out-licensing, partnering, and fund raising. We will respectfully decline any CRO, CDMO requests
)
)
){kind=logo}
){kind=logo}
)
)
){kind=logo}
){kind=logo}